DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1105418
Title:
Adenosine Blockade with Radiotherapy to Enhance Responses of Breast Cancer to Immune Checkpoint Inhibitors
Descriptive Note:
[Technical Report, Final Report]
Corporate Author:
Weill Cornell Medicine
Report Date:
2020-05-01
Pagination or Media Count:
50
Abstract:
A majority of patients with advanced breast cancer are currently non-responsive to immune checkpoint blockade ICB due to a lack of intratumoral CD8 T cell infiltration. Localized radiation therapy RT can be used as a spark to trigger systemic immunity and render patients susceptible to ICB, mediating abscopal effects outside of the irradiated field and occasionally tumor clearance and long-lasting immune memory. The ability of the host to mount tumor-specific CD8 T cell responses is highly dependent on tumor infiltration of dendritic cells DCs, particularly conventional type I DCs cDC1. However, following RT, adenosine ADO accumulation in the tumor microenvironment TME acts to suppress both DC subsets and effector CD8 T cells thus limiting the immunogenic effect of RT. During the research project, we have described that high doses of RT induces a rapid increase in ADO levels in tumors and causes upregulation of key enzymes involved in generation of ADO on tumor cells. Moreover, we have shown that ADO-blockade by anti-CD73 antibody therapy promotes infiltration of cDC1 cells in irradiated tumors. Importantly, we demonstrate that ADO-blockade promotes synergy between RT and ICB to induce systemic immune responses in mouse models of metastatic breast cancer.
Distribution Statement:
[A, Approved For Public Release]
